+A -A

Comparative View:

1Q18 Create chart
Net sales revenues 1,005,982
Change in Fair Value of Biological Assets 42,579
Cost of Goods Sold -645,345
Depreciation / Amortization / exhaustion -97,752
Exhaustion of biological assets -31,146
Gross Profit 274,318
Selling Expenses -150,553
General and Administrative Expenses -37,428
Management Compensation -4,059
Other Operating Compensation 2,035
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 84,313
Financial Income 18,074
Financial Expenses -61,349
Income Before Income Tax and Social Contribution 41,038
Income and social contribution taxes - current -16,794
Income Tax and Social Contribution - Deferred 6,579
Effect profit from discontinued operation null
Net Income 30,823
Recurring Net Income 30,823
Recurring EBITDA 182,128
EBITDA Margin 18.1 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza